Log in to your Inderes Free account to see all free content on this page.

PILA PHARMA

3.45

SEK

+1.77 %

Less than 1K followers

PILA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

+1.77%

-15.85%

-8%

-13.75%

-10.62%

+163.36%

-28.12%

-

-60.61%

PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the painful rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.

Market cap

93.59M SEK

Turnover

55.63K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

29.4.

2025

General meeting '25

27.8.

2025

Interim report Q2'25

ShowingAll content types

Regulatory press release2/27/2025, 7:00 AM

PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY - 31 DECEMBER 2024)

Press release2/24/2025, 3:45 PM

PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A

Regulatory press release12/18/2024, 2:00 PM

PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release11/21/2024, 9:00 AM

PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE

Press release11/20/2024, 4:00 PM

PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS

Press release11/19/2024, 11:03 AM

PILA PHARMA AB Chairman & CEO increase their holdings

Press release11/14/2024, 7:50 AM

PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN"

Regulatory press release11/14/2024, 7:00 AM

PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN

Regulatory press release11/13/2024, 7:00 AM

PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE

Regulatory press release10/17/2024, 6:00 AM

PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN

Press release9/2/2024, 10:04 AM

CEO Gustav H. Gram increases holding in PILA PHARMA AB

Regulatory press release8/27/2024, 6:00 AM

PILA PHARMA publishes interim report (1 January - 30 June 2024)

Press release8/26/2024, 1:07 PM

PILA PHARMA INVITES TO INVESTOR Q&A & PRESENTATIONS

Regulatory press release7/25/2024, 6:00 PM

PILA PHARMA'S BOARD OF DIRECTORS ANNOUNCES COMPLETION OF A FULLY SUBSCRIBED DIRECTED ISSUE OF APPROXIMATELY SEK 10 MILLION

Regulatory press release7/24/2024, 4:00 PM

PILA PHARMA INKS AGREEMENT WITH LINDUS HEALTH ABOUT NEXT CLINICAL TRIAL WITH SAFETY AND OBESITY READOUTS

Regulatory press release7/16/2024, 3:00 PM

PILA PHARMA'S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A DIRECTED ISSUE OF SHARES OF APPROXIMATELY SEK 10.0 MILLION

Press release6/26/2024, 9:19 AM

Clarification: PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE

Press release6/26/2024, 6:00 AM

PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE

Press release5/15/2024, 11:26 AM

CEO Gustav H. Gram increases holding in Pila Pharma AB

Press release5/7/2024, 1:28 PM

PILA PHARMA RECEIVES AWARD OF INNOVATION GRANT

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.